逆转脓毒症引起的 T 细胞功能障碍：OX-40 来拯救？
Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?
机构信息
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Center of Excellence in Inflammation, Infectious Disease and Immunity, East Tennessee State University, Johnson City, Tennessee, USA.
出版信息
J Leukoc Biol. 2021 Apr;109(4):689-691. doi: 10.1002/JLB.3CE0720-468. Epub 2020 Sep 29.
Abstract
The study of Unsinger and colleagues provide important insights into OX40 mediated immunotherapy as a potential approach for the treatment of sepsis induced immune suppression.
摘要
昂辛格及其同事的研究为 OX40 介导的免疫疗法作为治疗脓毒症诱导免疫抑制的一种潜在方法提供了重要的见解。
相似文献
1
Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?逆转脓毒症引起的 T 细胞功能障碍：OX-40 来拯救？
J Leukoc Biol. 2021 Apr;109(4):689-691. doi: 10.1002/JLB.3CE0720-468. Epub 2020 Sep 29.
2
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.FcγRIIB 结合驱动 Fc 工程化 αOX40 抗体的激动剂活性，以刺激人肿瘤浸润性 T 细胞。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-000816.
3
Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?OX40激动剂抗体能否促进胃癌中抗肿瘤免疫反应的激活？
J Surg Oncol. 2018 Apr;117(5):840-844. doi: 10.1002/jso.25001. Epub 2018 Mar 12.
4
Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration.白细胞介素-7、抗 PD-L1 和 OX-40 给药后治疗多重耐药菌脓毒症患者 T 细胞功能障碍
PLoS One. 2018 Jun 26;13(6):e0199497. doi: 10.1371/journal.pone.0199497. eCollection 2018.
5
Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.仿生纳米颗粒递送编码共刺激受体的 mRNAs，并增强 T 细胞介导的癌症免疫治疗。
Nat Commun. 2021 Dec 14;12(1):7264. doi: 10.1038/s41467-021-27434-x.
6
OX40: Structure and function - What questions remain?OX40：结构与功能——还有哪些问题有待解决？
Mol Immunol. 2017 Mar;83:13-22. doi: 10.1016/j.molimm.2017.01.006. Epub 2017 Jan 13.
7
Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.增强与抑制：联合OX-40受体单克隆抗体和白细胞介素-2治疗对晚期肿瘤过继性免疫治疗的影响
J Immunol. 2001 Dec 1;167(11):6669-77. doi: 10.4049/jimmunol.167.11.6669.
8
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.OX40、4-1BB 和 CD40 作为癌症免疫治疗的靶点。
Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14.
9
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.双抗 OX40/IL-2 疗法通过 IL-2R 介导的 OX40 表达调控增强肿瘤免疫治疗。
PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4.
10
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.抗 OX40 抗体直接增强肿瘤反应性 CD8 T 细胞的功能，并与 PTEN 缺失黑色素瘤中的 PI3Kβ 抑制协同作用。
Clin Cancer Res. 2019 Nov 1;25(21):6406-6416. doi: 10.1158/1078-0432.CCR-19-1259. Epub 2019 Aug 1.
引用本文的文献
1
Blood from septic patients with necrotising soft tissue infection treated with hyperbaric oxygen reveal different gene expression patterns compared to standard treatment.与标准治疗相比，接受高压氧治疗的患有坏死性软组织感染的脓毒症患者的血液呈现出不同的基因表达模式。
BMC Med Genomics. 2025 Jan 14;18(1):12. doi: 10.1186/s12920-024-02075-3.
2
Severity of Sepsis Determines the Degree of Impairment Observed in Circulatory and Tissue-Resident Memory CD8 T Cell Populations.脓毒症的严重程度决定了循环和组织驻留记忆 CD8 T 细胞群体中观察到的损伤程度。
J Immunol. 2021 Oct 1;207(7):1871-1881. doi: 10.4049/jimmunol.2001142. Epub 2021 Sep 3.
本文引用的文献
1
Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis.证据表明，脓毒症后发生慢性危重症的患者存在持续免疫抑制。
Shock. 2018 Mar;49(3):249-258. doi: 10.1097/SHK.0000000000000981.
2
OX40: Structure and function - What questions remain?OX40：结构与功能——还有哪些问题有待解决？
Mol Immunol. 2017 Mar;83:13-22. doi: 10.1016/j.molimm.2017.01.006. Epub 2017 Jan 13.
3
Late mortality after sepsis: propensity matched cohort study.脓毒症后的晚期死亡率：倾向匹配队列研究
BMJ. 2016 May 17;353:i2375. doi: 10.1136/bmj.i2375.
4
Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.脓毒症中的免疫抑制与继发感染：只是部分而非全部情况
JAMA. 2016 Apr 12;315(14):1457-9. doi: 10.1001/jama.2016.2762.
5
Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.评估全球医院治疗脓毒症的发病率和死亡率。当前的估计和局限性。
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. doi: 10.1164/rccm.201504-0781OC.
6
Why have clinical trials in sepsis failed?为什么脓毒症临床试验会失败？
Trends Mol Med. 2014 Apr;20(4):195-203. doi: 10.1016/j.molmed.2014.01.007. Epub 2014 Feb 24.
7
The search for effective therapy for sepsis: back to the drawing board?寻找脓毒症的有效治疗方法：要从头开始吗？
JAMA. 2011 Dec 21;306(23):2614-5. doi: 10.1001/jama.2011.1853.
8
OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis.OX40 配体调节败血症固有免疫反应中的炎症和死亡率。
J Immunol. 2010 Oct 15;185(8):4856-62. doi: 10.4049/jimmunol.1000404. Epub 2010 Sep 15.
9
Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.脓毒症诱导的细胞凋亡通过 TRAIL 依赖的机制导致 CD8+调节性 T 细胞对迟发型超敏反应的主动抑制。
J Immunol. 2010 Jun 15;184(12):6766-72. doi: 10.4049/jimmunol.0904054. Epub 2010 May 12.
10
A critical role for OX40 in T cell-mediated immunopathology during lung viral infection.OX40在肺部病毒感染期间T细胞介导的免疫病理中起关键作用。
J Exp Med. 2003 Oct 20;198(8):1237-42. doi: 10.1084/jem.20030351.
Zotero 插件